Bicara Therapeutics Inc. ... (BCAX)
NASDAQ: BCAX
· Real-Time Price · USD
17.04
0.33 (1.97%)
At close: Oct 03, 2025, 3:59 PM
16.92
-0.70%
After-hours: Oct 03, 2025, 05:42 PM EDT
1.97% (1D)
| Bid | 16.36 |
| Market Cap | 929.75M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102.67M |
| EPS (ttm) | -4.9 |
| PE Ratio (ttm) | -3.48 |
| Forward PE | -6.38 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 17.9 |
| Volume | 420,811 |
| Avg. Volume (20D) | 388,509 |
| Open | 16.71 |
| Previous Close | 16.71 |
| Day's Range | 16.42 - 17.85 |
| 52-Week Range | 7.80 - 28.09 |
| Beta | -0.78 |
| Ex-Dividend Date | n/a |
About BCAX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BCAX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BCAX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
-40.8%
Bicara Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
4 months ago
+7.33%
Bicara Therapeutics shares are trading lower after the company announced a publication of phase 1/1b trial data for ficerafusp alfa showing mixed results, with median survival still unreached and limited clarity on long-term efficacy.
